The Largest Dose of Wegovy: What Reaching the Maximum Means for Your Treatment

You've been on Wegovy for months and your progress has levelled off, here's what the new maximum means

Picture the situation many people find themselves in: they started Wegovy at 0.25mg, worked up carefully through the rungs of the titration schedule, settled at 2.4mg maintenance, and after several months feel their weight loss slowing. Until January 2026 that was largely the end of the road for Wegovy dosing. The MHRA's approval of 7.2mg changes that, there is now a licensed next step for adults whose prescriber judges it clinically appropriate.

The new 7.2mg pen, given the regulatory green light on 14 April 2026, is a single pre-set weekly injection rather than three separate 2.4mg pens. It has a built-in covered needle, an auto-dosing mechanism, and locks after use. Practically, that means one injection a week, same as before. The full Wegovy dose schedule now reads: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg → 7.2mg, with each step held for roughly four weeks minimum before any increase. A prescriber, not a chart on a wall, decides when or whether you move up.

Trial data at 7.2mg showed an average weight loss of around 20.7% over 72 weeks. For context, the STEP 1 trial reported roughly 15% average reduction at 2.4mg, published in the New England Journal of Medicine. The gap between the two doses is significant, and it's what drove MHRA approval. That said, clinical trials are controlled environments, individual results vary, and no prescriber can guarantee a specific outcome.

What the largest dose does differently inside the body

Semaglutide works by activating GLP-1 receptors, the same signals the gut releases after eating, which suppress appetite and slow how quickly food leaves the stomach. At 7.2mg, more of those receptors are occupied for longer. The practical effect most people notice is a more sustained reduction in hunger and a faster sense of fullness after smaller amounts of food.

The side-effect profile at higher doses tilts more heavily towards gastrointestinal symptoms (nausea, loose stools, and occasionally vomiting) than at lower doses. These tend to be most pronounced after a dose increase and settle over days to a couple of weeks for most people. Serious side effects, including acute pancreatitis, remain rare but real: the MHRA's Drug Safety Updates highlight severe or persistent stomach pain spreading to the back as a sign to seek medical help promptly, with or without vomiting. If something feels wrong, that's the right reflex.

One practical habit worth building if you're titrating up: check the injection-site guidance in your Patient Information Leaflet each time you increase dose. Rotating between abdomen, thigh, and upper arm consistently reduces localised reactions, and it takes under a minute to confirm you're not returning to the same spot. Small discipline, real difference. Exact storage windows for the new pen are in the leaflet too, always defer to those rather than any summary online.

Who actually reaches the largest Wegovy dose (and who doesn't need to

The 7.2mg dose is licensed for adults with a BMI of 30 or above) it is not approved for people with a BMI below 30, and it is not available for the cardiovascular indication. As the MHRA's April 2026 announcement makes clear, the obesity-management indication is the specific context for this approval. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance.

Whether someone reaches 7.2mg in practice depends on two things: how they're tolerating current doses, and whether clinical review supports moving up. Some people see substantial weight loss at 1.7mg or 2.4mg and have no clinical reason to go higher. Others plateau and benefit from the additional dose, and if you want to understand what reaching the strongest dose of Wegovy actually involves, including what clinical criteria tend to apply, that's worth reading before your next review. There's no virtue in reaching the maximum for its own sake. The decision belongs with a prescriber who knows your history, current medications, and how your body has responded so far. If you're curious about how the previous 2.4mg ceiling compared and why it's changed, that detail is worth understanding before your next review.

For people considering starting Wegovy (rather than titrating up) it helps to understand how the full dosing journey works from the start, since reaching any maintenance dose requires months of gradual adjustment. The Wegovy overview page covers licensing, eligibility, and how private treatment through a regulated pharmacy differs from waiting for an NHS referral.

Cost, availability, and the sensible next step

Reaching the largest dose of Wegovy also means being realistic about cost. Higher doses are typically priced higher per pen, and private treatment at 7.2mg represents a meaningful monthly commitment. The Wegovy price context page covers what the UK private market looks like and what a legitimate price actually includes, it's worth reading before comparing figures across providers.

Availability of the new 7.2mg pen varies by provider and changes as supply normalises. At nume (sorry, at nume) any dose availability is confirmed during clinical review rather than advertised in advance; stock positions change, and the prescriber's recommendation always takes priority over what's on a shelf. If you're already on treatment elsewhere and thinking about transferring, evidence of your current dose is part of the clinical intake process.

These are prescription-only medicines. The right way to access any dose of Wegovy is through clinical assessment with a prescriber who can see your full picture. If you'd like that assessment, start your free consultation, a GPhC-registered prescriber reads your answers the same day.